Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell

Cathleen Cover1, Peter Fickert, Tamara R Knight

  • 1Liver Research Institute, University of Arizona, Tucson, Arizona 85737, USA.

Insights

Acetaminophen overdose causes DNA damage in liver cells, but poly(ADP-ribose) polymerase-1 (PARP-1) activation is not responsible for liver injury. 3-aminobenzamide protects the liver through other mechanisms.

Area of Science:

  • Hepatotoxicity and Molecular Mechanisms
  • Pharmacology and Toxicology

Background:

  • Acetaminophen (AAP) overdose causes DNA fragmentation in hepatocytes, potentially leading to PARP activation and necrosis.
  • The specific role of PARP-1 activation in AAP-induced liver injury remains controversial due to conflicting results with chemical inhibitors.

Purpose of the Study:

  • To investigate PARP-1 activation following AAP overdose in a mouse model.
  • To evaluate the pathophysiological role of PARP-1 in AAP-induced hepatotoxicity using genetic and pharmacological approaches.

Main Methods:

  • Mice were treated with AAP (300 mg/kg) and assessed for DNA fragmentation and liver injury markers (ALT).
  • PARP-1 activation was measured by detecting poly-ADP-ribosylated proteins (PAR) in hepatocyte nuclei.
  • PARP inhibitors (3-aminobenzamide, 5-aminoisoquinolinone) and PARP gene knockout (PARP-/-) mice were used to assess PARP-1's role.

Main Results:

  • AAP treatment led to early DNA fragmentation and ALT release, with increased PAR-positive hepatocytes at later time points.
  • 3-aminobenzamide pretreatment significantly attenuated liver injury and DNA fragmentation, showing partial protection even with delayed treatment.
  • PARP-/- mice and wild-type mice treated with a specific PARP-1 inhibitor (5-aminoisoquinolinone) did not show reduced liver injury, indicating PARP-1 is not critical.

Conclusions:

  • PARP-1 activation is a consequence of DNA fragmentation after AAP overdose but not a key driver of oncotic necrosis.
  • The protective effect of 3-aminobenzamide against AAP-induced liver injury is independent of PARP-1 inhibition, likely due to reduced metabolic activation or antioxidant properties.